Brickell Biotech to Participate in March Virtual Investor Conferences

Rhea-AI Summary

Brickell Biotech, a clinical-stage pharmaceutical company (Nasdaq: BBI), announced CEO Robert Brown's participation in two upcoming conferences: the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, and the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021.

Both events will be held virtually, with opportunities for one-on-one meetings with management. Webcasts of the presentations will be accessible on Brickell's website for 90 days post-event, aiming to advance their mission in treating debilitating skin diseases.

BOULDER, Colo., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that Robert Brown, Brickell’s Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference and participate in a fireside chat at the Oppenheimer 31^st Annual Healthcare Conference, which are both being held in March 2021.

Details are as follows:

Conference: H.C. Wainwright Global Life Sciences Conference (virtual)
Date: Tuesday, March 9, 2021
Time: 7:00 AM EST
Management will be available throughout the day on March 10^th for virtual one-on-one meetings.

Conference: Oppenheimer 31^st Annual Healthcare Conference (virtual)
Date: Thursday, March 18, 2021
Time: 8:00 AM EDT
Management will be available throughout the day on March 17^th and 18^th for virtual one-on-one meetings.

Webcasts of the presentation at the H.C. Wainwright Global Life Sciences Conference and of the fireside chat at the Oppenheimer 31^st Annual Healthcare Conference will be available in the Investors section of the Brickell website at https://ir.brickellbio.com/events-presentations. The webcasts of both events will remain archived on the Brickell website for approximately 90 days.

About Brickell

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis^®, Taltz^®, Gemzar^®, Prozac^®, Cymbalta^® and Juvederm^®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs. For more information, visit https://www.brickellbio.com.

Brickell Investor Contact:
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com

 

FAQ

What is the date of the H.C. Wainwright Global Life Sciences Conference for Brickell Biotech?

The H.C. Wainwright Global Life Sciences Conference will be on March 9, 2021.

Where can I watch Brickell Biotech's conference presentations?

You can watch Brickell Biotech's conference presentations on their Investors section of the website.

When will Brickell Biotech participate in the Oppenheimer 31st Annual Healthcare Conference?

Brickell Biotech will participate in the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021.

What is the stock symbol for Brickell Biotech?

Brickell Biotech's stock symbol is BBI.

How long will the webcasts from Brickell Biotech's conferences be available?

The webcasts will be available for approximately 90 days after each event.